Business
Press Release Mar 16 2026
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis".
About this update from Sun Pharmaceutical Industries Limited
[{"type":"text","content":" Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 16, 2026, titled \"Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis\". View Attachment","length":463,"tagName":"div"}]